{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dementias&page=82",
    "query": {
      "condition": "Dementias",
      "page": 82
    },
    "page_size": 10
  },
  "pagination": {
    "page": 82,
    "page_size": 10,
    "total_count": 3012,
    "total_pages": 302,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dementias&page=83&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dementias&page=81&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T13:50:47.534Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01421056",
      "title": "Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "CHF 5074 1x",
          "type": "DRUG"
        },
        {
          "name": "CHF 5074 2x",
          "type": "DRUG"
        },
        {
          "name": "CHF 5074 3x",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiesi Farmaceutici S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 74,
      "start_date": "2011-07",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2014-02-06",
      "last_synced_at": "2026-11-21T13:50:47.534Z",
      "location_count": 4,
      "location_summary": "Eatontown, New Jersey • Monroe Twp, New Jersey • Toms River, New Jersey + 1 more",
      "locations": [
        {
          "city": "Eatontown",
          "state": "New Jersey"
        },
        {
          "city": "Monroe Twp",
          "state": "New Jersey"
        },
        {
          "city": "Toms River",
          "state": "New Jersey"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01421056"
    },
    {
      "nct_id": "NCT00141661",
      "title": "A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "PF-04494700 - Low Dose Arm",
          "type": "DRUG"
        },
        {
          "name": "PF-04494700 - High Dose Arm",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2005-10",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2009-08-20",
      "last_synced_at": "2026-11-21T13:50:47.534Z",
      "location_count": 12,
      "location_summary": "Sun City, Arizona • Fresno, California • San Diego, California + 9 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141661"
    },
    {
      "nct_id": "NCT00096473",
      "title": "Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Dementia"
      ],
      "interventions": [
        {
          "name": "Donepezil hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 229,
      "start_date": "2001-01",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2011-04-01",
      "last_synced_at": "2026-11-21T13:50:47.534Z",
      "location_count": 28,
      "location_summary": "Northport, Alabama • Phoenix, Arizona • Sun City, Arizona + 25 more",
      "locations": [
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096473"
    },
    {
      "nct_id": "NCT04124029",
      "title": "Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mild Traumatic Brain Injury",
        "Moderate Traumatic Brain Injury",
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "No Intervention is used for this study but all subjects will be asked to complete electroencephalogram (EEG) testing and an MRI scan.",
          "type": "DEVICE"
        },
        {
          "name": "No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "30 Years to 90 Years"
      },
      "enrollment_count": 800,
      "start_date": "2021-07-01",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-16",
      "last_synced_at": "2026-11-21T13:50:47.534Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04124029"
    },
    {
      "nct_id": "NCT04793659",
      "title": "Fasudil fOr redUcing elopemeNt and Spatial Disorientation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dementia"
      ],
      "interventions": [
        {
          "name": "Oral Fasudil 90 mg/day",
          "type": "DRUG"
        },
        {
          "name": "Oral Fasudil 180 mg/day",
          "type": "DRUG"
        },
        {
          "name": "Oral Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Woolsey Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 24,
      "start_date": "2020-12-15",
      "completion_date": "2022-02-11",
      "has_results": false,
      "last_update_posted_date": "2022-07-11",
      "last_synced_at": "2026-11-21T13:50:47.534Z",
      "location_count": 6,
      "location_summary": "Stamford, Connecticut • Lakeland, Florida • Miami Lakes, Florida + 3 more",
      "locations": [
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Toms River",
          "state": "New Jersey"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04793659"
    },
    {
      "nct_id": "NCT05877196",
      "title": "A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mild Cognitive Impairment",
        "Alzheimer Disease",
        "Cognitive Impairment",
        "Cognitive Decline",
        "Memory Loss",
        "Memory Impairment"
      ],
      "interventions": [
        {
          "name": "Moderate Intensity Continuous Training (MICT)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Chair-based Stretch",
          "type": "BEHAVIORAL"
        },
        {
          "name": "High-Intensity Interval Training (HIIT)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Combined Aerobic Resistance Exercise (CARE)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Arizona State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 216,
      "start_date": "2023-06-22",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-11-21T13:50:47.534Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05877196"
    },
    {
      "nct_id": "NCT03452956",
      "title": "Cognitive Impairement In Frontotemporal Dementia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Frontotemporal Degeneration",
        "Progressive Supranuclear Palsy",
        "Multiple System Atrophy"
      ],
      "interventions": [
        {
          "name": "None-Observation Only",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 997,
      "start_date": "2003-07-01",
      "completion_date": "2020-07-15",
      "has_results": false,
      "last_update_posted_date": "2020-11-12",
      "last_synced_at": "2026-11-21T13:50:47.534Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03452956"
    },
    {
      "nct_id": "NCT00948766",
      "title": "Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Rivastigmine 4.6 mg/24 h (5 cm^2)",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 9.5 mg/24 h (10 cm^2)",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 13.3 mg/24 h (15 cm^2)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 716,
      "start_date": "2009-07",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2013-08-28",
      "last_synced_at": "2026-11-21T13:50:47.534Z",
      "location_count": 93,
      "location_summary": "Tempe, Arizona • Tucson, Arizona • Conway, Arkansas + 84 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Conway",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00948766"
    },
    {
      "nct_id": "NCT02502253",
      "title": "BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mild Cognitive Impairment",
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "grape seed polyphenolic extract, resveratrol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 14,
      "start_date": "2015-06",
      "completion_date": "2022-06-01",
      "has_results": false,
      "last_update_posted_date": "2022-07-22",
      "last_synced_at": "2026-11-21T13:50:47.534Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02502253"
    },
    {
      "nct_id": "NCT03233646",
      "title": "Retinal Imaging in Neurodegenerative Disease",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alzheimer's Disease",
        "Mild Cognitive Impairment",
        "Parkinson's Disease",
        "Multiple Sclerosis",
        "Huntington Disease",
        "Lewy Body Dementia",
        "Frontotemporal Dementia",
        "Amyotrophic Lateral Sclerosis (ALS)",
        "APOE-4 Positive",
        "Traumatic Brain Injury",
        "Concussion",
        "Post-Traumatic Stress Disorder",
        "Down Syndrome",
        "Neuro-Degenerative Disease",
        "Normal Cognition"
      ],
      "interventions": [
        {
          "name": "Retinal and Choroidal Imaging",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2000,
      "start_date": "2017-07-20",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-11-21T13:50:47.534Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03233646"
    }
  ]
}